PRESS RELEASE

For Immediate Release - January 6, 2009

Tranzyme Pharma to Present at the 27th Annual JP Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C. (January 6, 2009) - Tranzyme Pharma, a clinical stage biopharmaceutical company engaged in the discovery and development of first-in-class small molecule therapeutics, announced today that Vipin K. Garg, Ph.D., President and CEO, will present at the upcoming 27th Annual JP Morgan Healthcare Conference being held from January 12-15, 2009. Tranzyme’s presentation will take place on Monday, January 12, 2009 at 8:30 a.m. PST at the Westin St. Francis Hotel in San Francisco, CA.

Dr. Garg will provide a corporate and product overview as well as a summary of positive clinical results for the company’s first-in-class, highly potent and selective ghrelin agonists, TZP-101 and TZP-102. During Q1 2009, TZP-101 is scheduled to enter a Phase 3 trial for the management of postoperative ileus (POI), and TZP-102 will enter into Phase 2 development for the treatment of gastroparesis.

About Tranzyme Pharma

Tranzyme Pharma is engaged in the discovery and development of breakthrough small molecule therapeutics for the treatment of both acute care (hospital-based) and chronic indications with significant unmet medical needs. In addition to TZP-101 and TZP-102, the company is developing a ghrelin antagonist, TZP-301, for the treatment of obesity and metabolic syndrome, and a motilin antagonist, TZP-201 for the treatment of various forms of moderate-to-severe diarrhea.

Tranzyme has developed a pipeline of novel drugs through its proprietary MATCH™ drug discovery technology which accelerates the progression of compounds from discovery to commercial track by generating small molecule drug candidates that display the favorable characteristics exhibited by large biomolecules, such as tight receptor binding for high potency and exquisite target selectivity, while maintaining the benefits typically associated with small molecule drugs including oral bioavailability, cost of synthesis, and ease of formulation. For more information, please visit: .